

Practical Experience with Continuous Subcutaneous Insulin Infusion Therapy in a Pediatric Diabetes Clinic

Michele A. O'Connell, MRCPI, and Fergus J. Cameron, M.D., FRACP

Abstract

Continuous subcutaneous insulin infusion therapy (CSII) is an increasingly popular form of intensive insulin administration in pediatric patients. The use of CSII commenced at our large tertiary referral diabetes clinic as recently as 2002. In the intervening years, demand and enthusiasm from both patients and physicians alike have resulted in a steady ongoing increase in CSII use at our clinic. We currently have >200 active patients using insulin pump therapy. This article reviews our experience with CSII and outlines our current multidisciplinary approach to optimizing glycemic control and outcomes in this patient group.

J Diabetes Sci Technol 2008;2(1):91-97

Author Affiliation: Department of Endocrinology and Diabetes, Royal Children's Hospital, Melbourne, Victoria, Australia

Abbreviations: (BGL) blood glucose level, (CHO) carbohydrate, (CSII) continuous subcutaneous insulin infusion, (DKA) diabetic ketoacidosis, (ED) eating disorder, (HbA1c) hemoglobin A1c, (MDI) multiple daily injections, (QOL) quality of life, (RCTs) randomized controlled trials, (SMBG) self-monitoring of blood glucose, (TDD) total daily dose, (T1DM) type 1 diabetes mellitus

Keywords: continuous subcutaneous insulin infusion, insulin pump therapy, pediatrics, type 1 diabetes

Corresponding Author: Fergus J. Cameron, M.D., FRACP, Head of Diabetes Services, Department of Endocrinology and Diabetes, Royal Children's Hospital, Parkville, Melbourne, Victoria 3052, Australia; email address fergus.cameron@rch.org.au